Malignant NeoplasmPhase 3MISTNCT03839940
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
A Phase 3 study testing Dexamethasone, Questionnaire and Quality-of-Life Assessment in people with Malignant Neoplasm, run by Alliance for Clinical Trials in Oncology at 319 sites in United States.
Trial summary
This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Malignant Neoplasm
- What is being tested?
- Dexamethasone, Questionnaire and Quality-of-Life Assessment
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 39 participants
- Where
- 319 sitesUnited States
- Study dates
- 3 Jun 2019to 3 Aug 2022
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Current cancer diagnosis, about to receive oral everolimus 10 mg/day with or without an endocrine agent. Patients about to receive everolimus for off label use for any cancer are also eligible.
- Not currently receiving chemotherapy or any other agent known to cause mucositis or stomatitis. Trastuzumab and ovarian function suppression are allowed.
- Any prior chemotherapy or other stomatitis/mucositis-causing therapy must be completed at least 2 weeks prior to registration.
- Not currently suffering from stomatitis/mucositis or mouth ulcers. Patients should not have had any stomatitis or mouth pain for at least 7 days prior to registration.
- Patients should not receive any other agent which would be considered treatment for stomatitis or impact the primary endpoint.
- No history of candida infection (thrush) within the last 3 months.
Show all 11Show fewer
- Not currently being treated with corticosteroids.
- No uncontrolled diabetes mellitus, defined by hemoglobin A1C greater than 8%, although A1C is not needed for all patients, hemoglobin (Hgb)A1C < 8 is required for everyone with diabetes or suspected diabetes.
- Patients must be able to read and comprehend English. Local translation, including verbal translation of professionals (PROs) is not permitted.
- Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
Who cannot join
None listed.
Trial locations and contacts
319 sites in 1 country.
300 sites in 1 country
United States300 sites
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Community Hospital of Anaconda
Anaconda, Montana, 59711
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
PCR Oncology
Arroyo Grande, California, 93420
Hematology Oncology Associates of Central New York-Auburn
Auburn, New York, 13021
Rush - Copley Medical Center
Aurora, Illinois, 60504
Saint Alphonsus Medical Center-Baker City
Baker City, Oregon, 97814
Saint Louis Cancer and Breast Institute-Ballwin
Ballwin, Missouri, 63011
Bronson Battle Creek
Battle Creek, Michigan, 49017
Overlake Medical Center
Bellevue, Washington, 98004
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Billings Clinic Cancer Center
Billings, Montana, 59101
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Cox Cancer Center Branson
Branson, Missouri, 65616
Lafayette Family Cancer Center-EMMC
Brewer, Maine, 04412
IHA Hematology Oncology Consultants-Brighton
Brighton, Michigan, 48114
Saint Joseph Mercy Brighton
Brighton, Michigan, 48114
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, 83605
Cambridge Medical Center
Cambridge, Minnesota, 55008
Illinois CancerCare-Canton
Canton, Illinois, 61520
IHA Hematology Oncology Consultants-Canton
Canton, Michigan, 48188
Saint Joseph Mercy Canton
Canton, Michigan, 48188
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Caro Cancer Center
Caro, Michigan, 48723
Carson Tahoe Regional Medical Center
Carson City, Nevada, 89703
SIH Cancer Institute
Carterville, Illinois, 62918
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Physicians' Clinic of Iowa PC
Cedar Rapids, Iowa, 52402
Centralia Oncology Clinic
Centralia, Illinois, 62801
IHA Hematology Oncology Consultants-Chelsea
Chelsea, Michigan, 48118
Saint Joseph Mercy Chelsea
Chelsea, Michigan, 48118
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376
Hematology Oncology Consultants-Clarkston
Clarkston, Michigan, 48346
Newland Medical Associates-Clarkston
Clarkston, Michigan, 48346
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Medical Center
Coeur d'Alene, Idaho, 83814
Mount Carmel East Hospital
Columbus, Ohio, 43213
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
Riverside Methodist Hospital
Columbus, Ohio, 43214
Grant Medical Center
Columbus, Ohio, 43215
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Mount Carmel Health Center West
Columbus, Ohio, 43222
Doctors Hospital
Columbus, Ohio, 43228
New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire, 03301
Mercy Hospital
Coon Rapids, Minnesota, 55433
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141
Carle on Vermilion
Danville, Illinois, 61832
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, 43015
Grady Memorial Hospital
Delaware, Ohio, 43015
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50309
Broadlawns Medical Center
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Ascension Saint John Hospital
Detroit, Michigan, 48236
Illinois CancerCare-Dixon
Dixon, Illinois, 61021
Epic Care-Dublin
Dublin, California, 94568
Dublin Methodist Hospital
Dublin, Ohio, 43016
Great Lakes Cancer Management Specialists-Doctors Park
East China Township, Michigan, 48054
Pocono Medical Center
East Stroudsburg, Pennsylvania, 18301
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin, 54701
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin, 54701
Mayo Clinic Health System Eau Claire Hospital-Luther Campus
Eau Claire, Wisconsin, 54703
Fairview Southdale Hospital
Edina, Minnesota, 55435
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
Bay Area Breast Surgeons Inc
Emeryville, California, 94608
Epic Care Partners in Cancer Care
Emeryville, California, 94608
Walter Knox Memorial Hospital
Emmett, Idaho, 83617
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Sanford South University Medical Center
Fargo, North Dakota, 58103
Southpointe-Sanford Medical Center Fargo
Fargo, North Dakota, 58103
Sanford Medical Center Fargo
Fargo, North Dakota, 58104
Sanford Broadway Medical Center
Fargo, North Dakota, 58122
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58122
Parkland Health Center - Farmington
Farmington, Missouri, 63640
Genesee Cancer and Blood Disease Treatment Center
Flint, Michigan, 48503
Genesee Hematology Oncology PC
Flint, Michigan, 48503
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Trinity Regional Medical Center
Fort Dodge, Iowa, 50501
Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Mercy Hospital Fort Smith
Fort Smith, Arkansas, 72903
Unity Hospital
Fridley, Minnesota, 55432
Central Ohio Breast and Endocrine Surgery
Gahanna, Ohio, 43230
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
CaroMont Regional Medical Center
Gastonia, North Carolina, 28054
Altru Cancer Center
Grand Forks, North Dakota, 58201
Helen DeVos Children's Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
Self Regional Healthcare
Greenwood, South Carolina, 29646
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Academic Hematology Oncology Specialists
Grosse Pointe Woods, Michigan, 48236
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, Michigan, 48236
Michigan Breast Specialists-Grosse Pointe Woods
Grosse Pointe Woods, Michigan, 48236
Mount Carmel Grove City Hospital
Grove City, Ohio, 43123
Lehigh Valley Hospital-Hazleton
Hazleton, Pennsylvania, 18201
Saint Peter's Community Hospital
Helena, Montana, 59601
Cancer and Blood Specialists-Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada-Horizon Ridge
Henderson, Nevada, 89052
Las Vegas Cancer Center-Henderson
Henderson, Nevada, 89052
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
21st Century Oncology-Henderson
Henderson, Nevada, 89074
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
Las Vegas Urology - Green Valley
Henderson, Nevada, 89074
Las Vegas Urology - Pebble
Henderson, Nevada, 89074
Urology Specialists of Nevada - Green Valley
Henderson, Nevada, 89074
Capital Region Southwest Campus
Jefferson City, Missouri, 65109
Freeman Health System
Joplin, Missouri, 64804
Mercy Hospital Joplin
Joplin, Missouri, 64804
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazoo, Michigan, 49048
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Kingman Regional Medical Center
Kingman, Arizona, 86401
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, 54601
Marshfield Clinic - Ladysmith Center
Ladysmith, Wisconsin, 54848
Fairfield Medical Center
Lancaster, Ohio, 43130
Sparrow Hospital
Lansing, Michigan, 48912
Las Vegas Urology - Pecos
Las Vegas, Nevada, 89074
Desert West Surgery
Las Vegas, Nevada, 89102
OptumCare Cancer Care at Oakey
Las Vegas, Nevada, 89102
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
Hope Cancer Care of Nevada
Las Vegas, Nevada, 89103
Cancer and Blood Specialists-Shadow
Las Vegas, Nevada, 89106
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, 89106
Urology Specialists of Nevada - Central
Las Vegas, Nevada, 89106
21st Century Oncology
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Las Vegas, Nevada, 89109
Sunrise Hospital and Medical Center
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-San Martin
Las Vegas, Nevada, 89113
Las Vegas Prostate Cancer Center
Las Vegas, Nevada, 89113
Las Vegas Urology - Sunset
Las Vegas, Nevada, 89113
Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada, 89119
21st Century Oncology-Vegas Tenaya
Las Vegas, Nevada, 89128
Ann M Wierman MD LTD
Las Vegas, Nevada, 89128
Cancer and Blood Specialists-Tenaya
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, 89128
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Las Vegas, Nevada, 89128
Las Vegas Urology - Cathedral Rock
Las Vegas, Nevada, 89128
Las Vegas Urology - Smoke Ranch
Las Vegas, Nevada, 89128
OptumCare Cancer Care at MountainView
Las Vegas, Nevada, 89128
Urology Specialists of Nevada - Northwest
Las Vegas, Nevada, 89128
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada, 89135
Comprehensive Cancer Centers of Nevada - Town Center
Las Vegas, Nevada, 89144
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Summerlin Hospital Medical Center
Las Vegas, Nevada, 89144
Las Vegas Cancer Center-Medical Center
Las Vegas, Nevada, 89148-2405
21st Century Oncology-Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Urology Specialists of Nevada - Southwest
Las Vegas, Nevada, 89148
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
Las Vegas, Nevada, 89149
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
University Cancer Center
Las Vegas, Nevada, 89169
Nebraska Hematology and Oncology
Lincoln, Nebraska, 68506
Southeast Nebraska Cancer Center - 68th Street Place
Lincoln, Nebraska, 68516
Hope Cancer Clinic
Livonia, Michigan, 48154
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, Michigan, 48044
Michigan Breast Specialists-Macomb Township
Macomb, Michigan, 48044
Solinsky Center for Cancer Care
Manchester, New Hampshire, 03103
OhioHealth Mansfield Hospital
Mansfield, Ohio, 44903
Fairview Clinics and Surgery Center Maple Grove
Maple Grove, Minnesota, 55369
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Marietta Memorial Hospital
Marietta, Ohio, 45750
OhioHealth Marion General Hospital
Marion, Ohio, 43302
Saint Mary's Oncology/Hematology Associates of Marlette
Marlette, Michigan, 48453
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Idaho Urologic Institute-Meridian
Meridian, Idaho, 83642
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
Community Medical Hospital
Missoula, Montana, 59804
Ochsner LSU Health Monroe Medical Center
Monroe, Louisiana, 71202
Monticello Cancer Center
Monticello, Minnesota, 55362
Virtua Samson Cancer Center
Moorestown, New Jersey, 08057
Virtua Memorial
Mount Holly, New Jersey, 08060
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Knox Community Hospital
Mount Vernon, Ohio, 43050
Mercy Health Mercy Campus
Muskegon, Michigan, 49444
Saint Alphonsus Medical Center-Nampa
Nampa, Idaho, 83686
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Licking Memorial Hospital
Newark, Ohio, 43055
Newark Radiation Oncology
Newark, Ohio, 43055
Lakeland Hospital Niles
Niles, Michigan, 49120
Faith Regional Health Services Carson Cancer Center
Norfolk, Nebraska, 68701
Great Plains Health Callahan Cancer Center
North Platte, Nebraska, 69101
Cancer and Hematology Centers of Western Michigan - Norton Shores
Norton Shores, Michigan, 49444
Cancer Care Center of O'Fallon
O'Fallon, Illinois, 62269
Alta Bates Summit Medical Center - Summit Campus
Oakland, California, 94609
Bay Area Tumor Institute
Oakland, California, 94609
Mercy Hospital Oklahoma City
Oklahoma City, Oklahoma, 73120
Nebraska Cancer Specialists - Omaha
Omaha, Nebraska, 68124
Oncology Hematology West PC
Omaha, Nebraska, 68130
Saint Alphonsus Medical Center-Ontario
Ontario, Oregon, 97914
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Hope Cancer Care of Nevada-Pahrump
Pahrump, Nevada, 89048
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Illinois CancerCare-Peru
Peru, Illinois, 61354
Valley Radiation Oncology
Peru, Illinois, 61354
21st Century Oncology-Pontiac
Pontiac, Michigan, 48341
Hope Cancer Center
Pontiac, Michigan, 48341
Newland Medical Associates-Pontiac
Pontiac, Michigan, 48341
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Huron Medical Center PC
Port Huron, Michigan, 48060
Lake Huron Medical Center
Port Huron, Michigan, 48060
Legacy Good Samaritan Hospital and Medical Center
Portland, Oregon, 97210
Southern Ohio Medical Center
Portsmouth, Ohio, 45662
Kootenai Cancer Center
Post Falls, Idaho, 83854
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Fairview Northland Medical Center
Princeton, Minnesota, 55371
Spectrum Health Reed City Hospital
Reed City, Michigan, 49677
Renown Regional Medical Center
Reno, Nevada, 89502
Saint Mary's Regional Medical Center
Reno, Nevada, 89503
Radiation Oncology Associates
Reno, Nevada, 89509
Valley Medical Center
Renton, Washington, 98055
Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin, 54868
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Great Lakes Cancer Management Specialists-Rochester Hills
Rochester Hills, Michigan, 48309
Delbert Day Cancer Institute at PCRMC
Rolla, Missouri, 65401
Mercy Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, 65401
Ascension Saint Mary's Hospital
Saginaw, Michigan, 48601
Oncology Hematology Associates of Saginaw Valley PC
Saginaw, Michigan, 48604
Lakeland Medical Center Saint Joseph
Saint Joseph, Michigan, 49085
Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, 63670
Kootenai Cancer Clinic
Sandpoint, Idaho, 83864
Regional West Medical Center Cancer Center
Scottsbluff, Nebraska, 69361
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Welch Cancer Center
Sheridan, Wyoming, 82801
LSU Health Sciences Center at Shreveport
Shreveport, Louisiana, 71103
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota, 57104
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, 57117-5134
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Springfield Clinic
Springfield, Illinois, 62702
Memorial Medical Center
Springfield, Illinois, 62781
Mercy Medical Center
Springfield, Massachusetts, 01104
Mercy Hospital Springfield
Springfield, Missouri, 65804
CoxHealth South Hospital
Springfield, Missouri, 65807
Saint Louis Cancer and Breast Institute-South City
St Louis, Missouri, 63109
Washington University School of Medicine
St Louis, Missouri, 63110
Mercy Hospital South
St Louis, Missouri, 63128
Siteman Cancer Center-South County
St Louis, Missouri, 63129
Missouri Baptist Medical Center
St Louis, Missouri, 63131
Siteman Cancer Center at Christian Hospital
St Louis, Missouri, 63136
Mercy Hospital Saint Louis
St Louis, Missouri, 63141
Bhadresh Nayak MD PC-Sterling Heights
Sterling Heights, Michigan, 48312
Marshfield Clinic Stevens Point Center
Stevens Point, Wisconsin, 54482
Lakeview Hospital
Stillwater, Minnesota, 55082
Missouri Baptist Sullivan Hospital
Sullivan, Missouri, 63080
Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills, Missouri, 63127
Southwest Illinois Health Services LLP
Swansea, Illinois, 62226
Hematology Oncology Associates of Central New York-Onondaga Hill
Syracuse, New York, 13215
Ascension Saint Joseph Hospital
Tawas City, Michigan, 48764
Sanford Thief River Falls Medical Center
Thief River Falls, Minnesota, 56701
Munson Medical Center
Traverse City, Michigan, 49684
Legacy Meridian Park Hospital
Tualatin, Oregon, 97062
Carle Cancer Center
Urbana, Illinois, 61801
The Carle Foundation Hospital
Urbana, Illinois, 61801
Legacy Cancer Institute Medical Oncology and Day Treatment
Vancouver, Washington, 98684
Legacy Salmon Creek Hospital
Vancouver, Washington, 98686
Virtua Voorhees
Voorhees Township, New Jersey, 08043
Ridgeview Medical Center
Waconia, Minnesota, 55387
Epic Care Cyberknife Center
Walnut Creek, California, 94597
Advanced Breast Care Center PLLC
Warren, Michigan, 48088
Great Lakes Cancer Management Specialists-Macomb Professional Building
Warren, Michigan, 48093
About this study
Official title: Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.
Read the detailed description
PRIMARY OBJECTIVES:
- To determine if the initiation of dexamethasone at the start of everolimus treatment prevents mTOR inhibitor-associated stomatitis (mIAS)-associated pain, compared to the initiation of placebo.
II. To determine if the initiation of dexamethasone at the start of everolimus treatment will be superior compared to the initiation of placebo in terms of the overall severity of mIAS-associated pain.
SECONDARY OBJECTIVES:
- To utilize the same measurement method that was reported in the SWISH trial: A combination of a patient reported pain scale, data from a normalcy of diet questionnaire, and clinician grading of stomatitis to determine the incidence of > grade 2 mIAS.
II. To determine if the initiation of dexamethasone at the start of everolimus increases time to development of mouth pain using daily numerical analog scale patient-reported data collection.
III. To assess if quality of life is better when dexamethasone mouth rinse use starts at the same time as everolimus use versus at the time when mouth pain begins.
IV. To investigate if starting dexamethasone mouth rinse concurrent with starting everolimus improves patients' ability to adhere to everolimus therapy.
- To compare dexamethasone prescription fill rates and timing between patients who received placebo versus study drug at the initiation of everolimus.
Trial Design:
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive everolimus orally (PO) once daily (QD) as standard of care and dexamethasone as mouthwash over 2 minutes 4 times per day (QID) for 8 weeks.
GROUP II: Patients receive everolimus PO QD as standard of care and placebo as mouthwash over 2 minutes QID for 8 weeks.
- Conditions
- Malignant Neoplasm
- Being tested
- Dexamethasone, Placebo, Questionnaire, Quality-of-Life Assessment, Everolimus
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DexamethasoneDrug
Given as mouthwash
PlaceboOther
Given as mouthwash
QuestionnaireOther
Ancillary studies
Quality-of-Life AssessmentOther
Ancillary studies
EverolimusDrug
Standard of care
| Study group | Role | What they receive |
|---|---|---|
| Group I (dexamethasone) | Experimental | Patients receive 10mg oral everolimus daily as standard of care and 10ml dexamethasone oral mouthwash, swished for 2-minutes daily, for 8 weeks. Receives: Drug: Dexamethasone; Other: Questionnaire; Other: Quality-of-Life Assessment; Drug: Everolimus |
| Group II (placebo) | Placebo comparator | Patients receive 10mg oral everolimus daily as standard of care and 10ml placebo oral mouthwash, swished for 2-minutes daily, for 8 weeks. Receives: Other: Placebo; Other: Questionnaire; Other: Quality-of-Life Assessment; Drug: Everolimus |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence Rate of the mTOR Inhibitor-associated Stomatitis (mIAS)-Related Pain Based on Daily Self-reports Via the Numerical Analogue Scale
The numerical analogue mouth pain score (NAMPS) is a single item measured on a 0 to 10 scale, with 0 corresponding to "No pain" and 10 corresponding to "Pain as bad as it can be." Will compare the incidence rate of any mouth pain (i.e., any score greater than 0) as assessed by the NAMPS between the prevention versus early treatment approaches using a Chi-square test.
Measured: Up to 8 weeks
Severity of Mouth Pain Scores
Average Area Under the Curve per assessment (aAUCpa) of mouth pain scores as measured by NAMPS will be computed for each patient to summarize the sequence of numerical analogue mouth pain scores over the eight week study period. Scores are reported on a 0-100 scale, where 100 = better outcome QOL (i.e. less pain). The aAUCpa is the average of each AUC between each sequential assessment from treatment-initiation to the end of the treatment at 8 weeks post-treatment-initiation and will be compared between the two treatment arms.
Measured: Up to 8 weeks
Secondary outcomes (15)
Incidence of Grade > 2 mIAS as Measured by the SWISH Trial
Original plan for collecting and analyzing this data did not occur due to study termination.
Grade 2 mIAS is defined as having at least one of the following criteria:>
- Oral intake assessed at 50 on the Normalcy of Diet Scale
- Patient's reported oral pain (using visual analogue scale 0-10) that meets one of the following: rating of 7 on two consecutive days rating of 8, 9, or 10 on any one day. The incidence of grade 2 mIAS for each treatment arm will be compared by a Chi-square test.
Measured: Up to 8 weeks
Incidence of Mouth Pain
Original plan for collecting and analyzing this data did not occur due to study termination.
Will determine if the initiation of dexamethasone at the start of everolimus is associated with the incidence and of mild (score of 1-3), moderate (score of 4-6) and severe (score of 7-10) mouth pain as measured by the NAMPS. Will be assessed by Chi-square tests.
Measured: Up to 8 weeks
Time to Development of Mouth Pain
Original plan for collecting and analyzing this data did not occur due to study termination.
Will determine if the initiation of dexamethasone at the start of everolimus is associated with the time to development of mild (score of 1-3), moderate (score of 4-6) and severe (score of 7-10) mouth pain as measured by the NAMPS. Will be assessed by Kaplan-Meier and cumulative incidence curves.
Measured: Up to 8 weeks
Quality of Life Assessed by Linear Analogue Self-Assessment
Original plan for collecting and analyzing this data did not occur due to study termination.
Will determine if the initiation of dexamethasone at the start of everolimus is associated with quality of life is by comparing numerical analogue scale scores as measured by the Linear Analogue Self-Assessment. The Linear Analogue Self Assessment for quality of life is measured on a 0 to 10 scale, with 0 corresponding to "Quality of life as bad as it can be" and 10 corresponding to "Quality of life as good as it can be." Will be assessed by independent samples t-tests.
Measured: Up to 8 weeks
Mouth/Throat Sore Level of Activity Interference With Daily Activities
Original plan for collecting and analyzing this data did not occur due to study termination.
Will determine if the initiation of dexamethasone at the start of everolimus is associated with the level of interference with daily activities as measured by the Patient Reported Outcome (PRO) Common Terminology criteria for Adverse Events (CTCAE) mouth/throat item regarding level of interference with daily activities. The PRO-CTCAE mouth/throat item regarding level of interference with daily activities is measured on a Likert 1-5 scale, with 1 corresponding to "Not at all" and 5 corresponding to "Very much." Will be assessed by independent samples t-tests.
Measured: Up to 8 weeks
Sleep Level of Activity Interference With Daily Activities
Original plan for collecting and analyzing this data did not occur due to study termination.
Will determine if the initiation of dexamethasone at the start of everolimus is associated with the level of interference with daily activities as measured by the PRO-CTCAE sleep item regarding level of interference with daily activities. The PRO-CTCAE sleep item regarding level of interference with daily activities is measured on a Likert 1-5 scale, with 1 corresponding to "Not at all" and 5 corresponding to "Very much." Will be assessed by independent samples t-tests.
Measured: Up to 8 weeks
Adherence to Everolimus Therapy Dose
Original plan for collecting and analyzing this data did not occur due to study termination.
Will compare mean daily dose of everolimus between the arms. The mean daily dose of everolimus over 8 weeks will be compared between study arms using independent samples t-tests.
Measured: Up to 8 weeks
Incidence of Patients Stopping Everolimus Early
Original plan for collecting and analyzing this data did not occur due to study termination.
Will compare the number of patients who stopped everolimus early between the treatment arms. Will be compared using Chi-squared tests.
Measured: Up to 8 weeks
Incidence of Patients Reducing Everolimus Dose
Original plan for collecting and analyzing this data did not occur due to study termination.
Will compare the number of patients who reduced their everolimus dose between the treatment arms. Will be compared using Chi-squared tests.
Measured: Up to 8 weeks
Dexamethasone Prescription Fill Rates
Original plan for collecting and analyzing this data did not occur due to study termination.
Will compare dexamethasone prescription fill rates between the treatment groups. This will be compared using Chi-squared tests.
Measured: Up to 8 weeks
Time to Dexamethasone Prescription Fill
Original plan for collecting and analyzing this data did not occur due to study termination.
Will compare the time to dexamethasone prescription fill between the treatment groups. This will be compared using Kaplan-Meier and cumulative incidence curves.
Measured: Up to 8 weeks
Time to Develop Mouth Sores Per Study Arm Assessed by PRO-CTCAE Mouth/Throat Sore Item Regarding Severity
Original plan for collecting and analyzing this data did not occur due to study termination.
The time to develop at least mild, moderate, or severe (including "Very severe") mouth sores per study arm as measured by the PRO-CTCAE mouth-throat sore item regarding severity. The PRO-CTCAE mouth-throat sore item regarding severity is measured on a Likert 1-5 scale, with 1 corresponding to "None" and 5 corresponding to "Very severe". Will be assessed by Kaplan-Meier and cumulative incidence curves.
Measured: Up to 8 weeks
Mean Degrees of Patient-reported Mouth Sores Per Study Arm Assessed by NAMPS
Original plan for collecting and analyzing this data did not occur due to study termination.
The mean degrees of patient-reported mouth sores per study arm as measured by the NAMPS will be assessed by independent samples t-tests.
Measured: Up to 8 weeks
Median Degree of Patient-reported Mouth Sores Per Study Arm Assessed by NAMPS
Original plan for collecting and analyzing this data did not occur due to study termination.
The median degrees of patient-reported mouth sores per study arm as measured by the NAMPS will be assessed by independent samples t-tests.
Measured: Up to 8 weeks
Proportion of Patients Who Experience Grade 2 Stomatitis
Original plan for collecting and analyzing this data did not occur due to study termination.
The proportion of patients who experience clinician-reported grade 2 stomatitis (as measured by the CTCAE and performed at 1 and 2 months post-baseline) per study arm will be assessed by Chi-squared tests.
Measured: Up to 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Feb 2019
- Study start3 Jun 2019
- Primary completion8 Jan 2021
- Study completion3 Aug 2022
Why it stopped: Severe lack of accrual
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Malignant NeoplasmStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 39 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Kathryn Ruddy, MD, Study chair, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03839940
- Sponsor's protocol ID
- A221701
- Other IDs
- NCI-2018-02648, UG1CA189823
- Acronym
- MIST
- Status last verified
- Jan 2025
- First submitted
- 6 Feb 2019
- Last updated
- 29 Jan 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive
Publications
Ruddy KJ, Zahrieh D, He J, Waechter B, Holleran JL, Lewis LD, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo HS, Loprinzi C. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Semin Oncol. 2023 Feb-Apr;50(1-2):7-10. doi: 10.1053/j.seminoncol.2023.01.001. Epub 2023 Jan 17.
PubMed 36693773
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
- ClinicalTrials.gov ID
- NCT03839940
- Acronym / sponsor ID
- MIST / A221701
- Conditions
- Malignant Neoplasm
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Severe lack of accrual
- Enrolment
- 39 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 3 Jun 2019 (actual)
- Primary completion
- 8 Jan 2021 (actual)
- Study completion
- 3 Aug 2022 (actual)
- First posted
- 15 Feb 2019 (actual)
- Results
- Posted 1 Aug 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.
Detailed description
PRIMARY OBJECTIVES:
- To determine if the initiation of dexamethasone at the start of everolimus treatment prevents mTOR inhibitor-associated stomatitis (mIAS)-associated pain, compared to the initiation of placebo.
II. To determine if the initiation of dexamethasone at the start of everolimus treatment will be superior compared to the initiation of placebo in terms of the overall severity of mIAS-associated pain.
SECONDARY OBJECTIVES:
- To utilize the same measurement method that was reported in the SWISH trial: A combination of a patient reported pain scale, data from a normalcy of diet questionnaire, and clinician grading of stomatitis to determine the incidence of > grade 2 mIAS.
II. To determine if the initiation of dexamethasone at the start of everolimus increases time to development of mouth pain using daily numerical analog scale patient-reported data collection.
III. To assess if quality of life is better when dexamethasone mouth rinse use starts at the same time as everolimus use versus at the time when mouth pain begins.
IV. To investigate if starting dexamethasone mouth rinse concurrent with starting everolimus improves patients' ability to adhere to everolimus therapy.
- To compare dexamethasone prescription fill rates and timing between patients who received placebo versus study drug at the initiation of everolimus.
Trial Design:
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive everolimus orally (PO) once daily (QD) as standard of care and dexamethasone as mouthwash over 2 minutes 4 times per day (QID) for 8 weeks.
GROUP II: Patients receive everolimus PO QD as standard of care and placebo as mouthwash over 2 minutes QID for 8 weeks.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group I (dexamethasone) | Experimental | Drug: Dexamethasone, Other: Questionnaire, Other: Quality-of-Life Assessment, Drug: EverolimusPatients receive 10mg oral everolimus daily as standard of care and 10ml dexamethasone oral mouthwash, swished for 2-minutes daily, for 8 weeks. |
| Group II (placebo) | Placebo comparator | Other: Placebo, Other: Questionnaire, Other: Quality-of-Life Assessment, Drug: EverolimusPatients receive 10mg oral everolimus daily as standard of care and 10ml placebo oral mouthwash, swished for 2-minutes daily, for 8 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Current cancer diagnosis, about to receive oral everolimus 10 mg/day with or without an endocrine agent. Patients about to receive everolimus for off label use for any cancer are also eligible.
- Not currently receiving chemotherapy or any other agent known to cause mucositis or stomatitis. Trastuzumab and ovarian function suppression are allowed.
- Any prior chemotherapy or other stomatitis/mucositis-causing therapy must be completed at least 2 weeks prior to registration.
- Not currently suffering from stomatitis/mucositis or mouth ulcers. Patients should not have had any stomatitis or mouth pain for at least 7 days prior to registration.
- Patients should not receive any other agent which would be considered treatment for stomatitis or impact the primary endpoint.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DexamethasoneGiven as mouthwash | Drug | Group I (dexamethasone) |
| PlaceboGiven as mouthwash | Other | Group II (placebo) |
| QuestionnaireAncillary studies | Other | Group I (dexamethasone), Group II (placebo) |
| Quality-of-Life AssessmentAncillary studies | Other | Group I (dexamethasone), Group II (placebo) |
| EverolimusStandard of care | Drug | Group I (dexamethasone), Group II (placebo) |
Primary outcome
Incidence Rate of the mTOR Inhibitor-associated Stomatitis (mIAS)-Related Pain Based on Daily Self-reports Via the Numerical Analogue Scale
Time frame: Up to 8 weeks
The numerical analogue mouth pain score (NAMPS) is a single item measured on a 0 to 10 scale, with 0 corresponding to "No pain" and 10 corresponding to "Pain as bad as it can be." Will compare the incidence rate of any mouth pain (i.e., any score greater than 0) as assessed by the NAMPS between the prevention versus early treatment approaches using a Chi-square test.
Severity of Mouth Pain Scores
Time frame: Up to 8 weeks
Average Area Under the Curve per assessment (aAUCpa) of mouth pain scores as measured by NAMPS will be computed for each patient to summarize the sequence of numerical analogue mouth pain scores over the eight week study period. Scores are reported on a 0-100 scale, where 100 = better outcome QOL (i.e. less pain). The aAUCpa is the average of each AUC between each sequential assessment from treatment-initiation to the end of the treatment at 8 weeks post-treatment-initiation and will be compared between the two treatment arms.
15 secondary outcomes
Incidence of Grade > 2 mIAS as Measured by the SWISH Trial
Time frame: Up to 8 weeks
Incidence of Mouth Pain
Time frame: Up to 8 weeks
Time to Development of Mouth Pain
Time frame: Up to 8 weeks
Quality of Life Assessed by Linear Analogue Self-Assessment
Time frame: Up to 8 weeks
Mouth/Throat Sore Level of Activity Interference With Daily Activities
Time frame: Up to 8 weeks
Sleep Level of Activity Interference With Daily Activities
Time frame: Up to 8 weeks
Adherence to Everolimus Therapy Dose
Time frame: Up to 8 weeks
Incidence of Patients Stopping Everolimus Early
Time frame: Up to 8 weeks
Incidence of Patients Reducing Everolimus Dose
Time frame: Up to 8 weeks
Dexamethasone Prescription Fill Rates
Time frame: Up to 8 weeks
Time to Dexamethasone Prescription Fill
Time frame: Up to 8 weeks
Time to Develop Mouth Sores Per Study Arm Assessed by PRO-CTCAE Mouth/Throat Sore Item Regarding Severity
Time frame: Up to 8 weeks
Mean Degrees of Patient-reported Mouth Sores Per Study Arm Assessed by NAMPS
Time frame: Up to 8 weeks
Median Degree of Patient-reported Mouth Sores Per Study Arm Assessed by NAMPS
Time frame: Up to 8 weeks
Proportion of Patients Who Experience Grade 2 Stomatitis
Time frame: Up to 2 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 36693773Ruddy KJ, Zahrieh D, He J, Waechter B, Holleran JL, Lewis LD, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo HS, Loprinzi C. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Semin Oncol. 2023 Feb-Apr;50(1-2):7-10. doi: 10.1053/j.seminoncol.2023.01.001. Epub 2023 Jan 17.
- Individual participant dataSharing planned: Yes. Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive
Related trials for Malignant Neoplasm
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Not yet recruiting
Augmented-Reality ICG Fluorescence Second-Look for Residual Nodal Disease After Axillary Dissection in Breast Cancer
Breast Cancer, Breast Neoplasms
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
RecruitingPhase 3
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kathryn Ruddy, MD study chair
Mayo Clinic
319 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Dexamethasone, Questionnaire and Quality-of-Life Assessment in people with Malignant Neoplasm, run by Alliance for Clinical Trials in Oncology at 319 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 29 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 319 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 1 Aug 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence Rate of the mTOR Inhibitor-associated Stomatitis (mIAS)-Related Pain Based on Daily Self-reports Via the Numerical Analogue Scale (time frame: Up to 8 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03839940, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2025.